Literature DB >> 21813447

NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.

Iris H I M Hollink1, Marry M van den Heuvel-Eibrink, Susan T C J M Arentsen-Peters, Marta Pratcorona, Saman Abbas, Jenny E Kuipers, Janneke F van Galen, H Berna Beverloo, Edwin Sonneveld, Gert-Jan J L Kaspers, Jan Trka, Andre Baruchel, Martin Zimmermann, Ursula Creutzig, Dirk Reinhardt, Rob Pieters, Peter J M Valk, C Michel Zwaan.   

Abstract

Translocations involving nucleoporin 98kD (NUP98) on chromosome 11p15 occur at relatively low frequency in acute myeloid leukemia (AML) but can be missed with routine karyotyping. In this study, high-resolution genome-wide copy number analyses revealed cryptic NUP98/NSD1 translocations in 3 of 92 cytogenetically normal (CN)-AML cases. To determine their exact frequency, we screened > 1000 well-characterized pediatric and adult AML cases using a NUP98/NSD1-specific RT-PCR. Twenty-three cases harbored the NUP98/NSD1 fusion, representing 16.1% of pediatric and 2.3% of adult CN-AML patients. NUP98/NSD1-positive AML cases had significantly higher white blood cell counts (median, 147 × 10⁹/L), more frequent FAB-M4/M5 morphology (in 63%), and more CN-AML (in 78%), FLT3/internal tandem duplication (in 91%) and WT1 mutations (in 45%) than NUP98/NSD1-negative cases. NUP98/NSD1 was mutually exclusive with all recurrent type-II aberrations. Importantly, NUP98/NSD1 was an independent predictor for poor prognosis; 4-year event-free survival was < 10% for both pediatric and adult NUP98/NSD1-positive AML patients. NUP98/NSD1-positive AML showed a characteristic HOX-gene expression pattern, distinct from, for example, MLL-rearranged AML, and the fusion protein was aberrantly localized in nuclear aggregates, providing insight into the leukemogenic pathways of these AMLs. Taken together, NUP98/NSD1 identifies a previously unrecognized group of young AML patients, with distinct characteristics and dismal prognosis, for whom new treatment strategies are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813447     DOI: 10.1182/blood-2011-04-346643

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  98 in total

1.  The first Korean case of childhood acute myeloid leukemia with inv(11)(p15q22)/NUP98-DDX10 rearrangement: a rare but recurrent genetic abnormality.

Authors:  Rihwa Choi; Mi-Ae Jang; Keon Hee Yoo; Seung-Tae Lee; Hee-Jin Kim; Sun-Hee Kim
Journal:  Ann Lab Med       Date:  2014-10-28       Impact factor: 3.464

2.  Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease.

Authors:  Marjolein Blink; Marry M van den Heuvel-Eibrink; Valerie de Haas; Jan-Henning Klusmann; Henrik Hasle; C Michel Zwaan
Journal:  Haematologica       Date:  2012-04       Impact factor: 9.941

3.  Identification of MYC mutations in acute myeloid leukemias with NUP98-NSD1 translocations.

Authors:  V-P Lavallée; S Lemieux; G Boucher; P Gendron; I Boivin; S Girard; J Hébert; G Sauvageau
Journal:  Leukemia       Date:  2016-02-09       Impact factor: 11.528

Review 4.  Using genomics to define pediatric blood cancers and inform practice.

Authors:  Rachel E Rau; Mignon L Loh
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

5.  A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis.

Authors:  Carolien M Woolthuis; André B Mulder; Rikst Nynke Verkaik-Schakel; Stefano Rosati; Arjan Diepstra; Eva van den Berg; Jan Jacob Schuringa; Edo Vellenga; Philip M Kluin; Gerwin Huls
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

Review 6.  Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes.

Authors:  Birgit Knoechel; Jens G Lohr
Journal:  J Autoimmun       Date:  2013-07-21       Impact factor: 7.094

7.  Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.

Authors:  Angeliki Thanasopoulou; Alexandar Tzankov; Juerg Schwaller
Journal:  Haematologica       Date:  2014-06-20       Impact factor: 9.941

8.  Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia.

Authors:  Jarno L Kivioja; Angeliki Thanasopoulou; Ashwini Kumar; Mika Kontro; Bhagwan Yadav; Muntasir M Majumder; Komal K Javarappa; Samuli Eldfors; Juerg Schwaller; Kimmo Porkka; Caroline A Heckman
Journal:  Leukemia       Date:  2018-12-19       Impact factor: 11.528

9.  The fusion partner specifies the oncogenic potential of NUP98 fusion proteins.

Authors:  Jesslyn Saw; David J Curtis; Damian J Hussey; Alexander Dobrovic; Peter D Aplan; Christopher I Slape
Journal:  Leuk Res       Date:  2013-09-21       Impact factor: 3.156

10.  Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia.

Authors:  A M Aalbers; R T Calado; N S Young; C M Zwaan; C Wu; S Kajigaya; E A Coenen; A Baruchel; K Geleijns; V de Haas; G J L Kaspers; T W Kuijpers; D Reinhardt; J Trka; M Zimmermann; R Pieters; V H J van der Velden; M M van den Heuvel-Eibrink
Journal:  Leukemia       Date:  2013-02-21       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.